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Hepatitis  C viral  infection  persists  and  becomes  chronic  in a  majority  of  affected  individuals.  Numerous
factors  have been  described  to explain  how  the  virus  manages  to  escape  the host  immune  system.  Onevailable online 6 July 2015
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important  escape  mechanism  is  the increase  in regulatory  T cells  induced  by the virus.  In this  review,  we
will  focus  on the  status  of  regulatory  T cells  throughout  the  natural  history  of  hepatitis  C infection  and
after  liver transplantation.  The  molecular  mechanisms  involved  in  increasing  the  number  of regulatory
T  cells  are  also  discussed,  as  are  data regarding  the  impact  of  regulatory  T-cells  on hepatic  ﬁbrosis  in  the
context  of  hepatitis  C  viral  infection.
 Gastransplantation © 2015  Editrice
. Introduction
Regulatory T cells (Treg) are a crucial component in the immune
ystem, maintaining self-tolerance and immune homeostasis. Treg
orm a highly heterogeneous population which can be broadly
ivided into two main subsets: thymus-derived “natural” Treg and
eripherally induced Treg. The most widely studied subsets are
oxP3+ Treg and Type 1 regulatory T-cells (Tr1).
FoxP3+ Treg are CD4+ T-cells that are characterized by expres-
ion of the interleukin 2 (IL2) receptor alpha chain (CD25),
xpression of the transcription factor FoxP3 and a weak expres-
ion of CD127 which discriminate them from activated CD4+
 cells [1–3]. Flow-cytometry immunophenotyping of FoxP3+ Treg
s usually based on labelling these four markers. Approximately
% to 10% of CD4+ T-cells from the peripheral blood of healthy
onors express CD25. CD4+ CD25+ T-cells are frequently used in
unctional suppressive assays as they mainly possess a regulatory
henotype and they can conveniently be isolated from peripheral
lood mononuclear cells (PBMC). Other markers of FoxP3+ Treg
nclude the regulatory molecules GITR, CTLA4, PD1, LAG3 and OX40
4,5].
The IL2 signalling pathway is essential for FoxP3+ Treg develop-
ent and homeostasis [6]. Both IL2 signalling and TCR activation
re also necessary for FoxP3+ Treg to become suppressive [7].
nce activated, they exert their suppressive functions in a
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non-speciﬁc manner [8]. The mechanisms of action of FoxP3+ Treg
are diverse and still not fully understood. They affect effector
T-cells through cell-to-cell contact inhibition of IL2 transcription,
metabolic disruption through CD39 and CD73 adenosine genera-
tion, direct cytotoxicity through granzyme A, and by acting as an
IL2 “sink”. They also modulate dendritic cell functions through the
interaction of CTLA4 with CD80/86 and that of LAG-3 with the
major histocompatibility complex (MHC) class II. The CTLA4 inter-
action triggers IDO activity and subsequently reduces T effector cell
proliferation by reducing tryptophan availability, while the LAG-
3 interaction inhibits dendritic cell (DC) activation. Finally, they
produce the regulatory cytokines TGF-beta, IL10 and IL35 [9].
FoxP3+ Treg are either natural or peripherally induced Treg.
While both FoxP3+ subsets display similar phenotypic characteris-
tics, they possess different mRNA and protein expression proﬁles
[10]. Helios expression has been proposed as a natural FoxP3+
Treg marker but may  lack speciﬁcity. Neuropilin-1 expression is
an interesting new lead but further studies are required to conﬁrm
its ability to discriminate natural FoxP3+ Treg from peripherally-
induced Treg [11]. In this review, no distinction shall be made
between FoxP3+ thymic Treg and FoxP3+ induced Treg, and they
will be referred to as FoxP3+ Treg.
Tr1 cells were ﬁrst described as IL10-secreting CD4+ T-cell
clones generated ex vivo through repetitive stimulation in the pres-
ence of IL10 [12]. These clones were able to suppress CD4+ T-cell
proliferation in a mouse model of colitis and they possess a cytokine
proﬁle that is distinct from T helper 1 (Th1) and Th2 cells, produc-
ing high levels of IL10 and low levels of IL2 and IL4. Since this initial
publication, the natural occurrence and functional role of Tr1 cells
in humans have been widely demonstrated [13].
 rights reserved.
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Speciﬁc markers for Tr1 cells have remained elusive. Transcrip-
ome analysis has shown that the CD49b and CD18 integrins are
ver-expressed in human and mouse Tr1 clones [14], and CD4+
-cells co-expressing CD49b and CD18 isolated from healthy
onors are reminiscent of Tr1 cells. The over-expression of CD49b
n Tr1 clones from healthy donors has been conﬁrmed by another
roup, but not the expression of CD18 [9]. Recently, the co-
xpression of CD49b and LAG-3 was proposed as a speciﬁc surface
arker for Tr1 cells in both mouse models and human PBMC from
ealthy donors [15].
Unlike FoxP3+ Treg, the survival of which is mainly reliant
n IL2, the survival and proliferation of Tr1 cells depends mainly
n IL15 and to a lesser extent on IL2 [16]. Tr1 cells exert their
uppressive activities by secreting high levels of the immuno-
uppressive cytokines IL10 and TGF beta. They also possess cell
ontact-dependent suppressive mechanisms through CTLA4 and
D-1, as well as a direct cytolytic activity through Granzyme B and
n ability to disrupt T-cell metabolism through the expression of
D39 and CD73, in the same way as FoxP3+ Treg [9].
Although the suppressive functions of Treg are crucial to main-
aining homeostasis of the immune system, their ability to inhibit
he host immune response may  be diverted in pathological con-
exts such as cancer or infection [17]. In the case of HCV infection,
reg levels are increased and favour persistence of the virus [18].
In this review we will focus on the status and role of Treg in the
stablishment of chronic HCV infection and in the speciﬁc context
f a post-transplantation recurrence of HCV infection.
. Establishment of persistent HCV infection
Chronic HCV infection represents a major global health problem
hat affects more than 160 million people across the world [19].
he initial infection is often asymptomatic and the virus is elimi-
ated by the host immune system in approximately 25% of cases. In
he remaining 75%, the virus persists in the host and the infection
ecomes chronic [20].
The strength and amplitude of the initial immune response
etermines the outcome of the infection. A strong CD4+ T-cell
esponse directed against multiple HCV protein epitopes has been
escribed during acute infection in patients who cleared the infec-
ion, while patients with a chronic outcome displayed a weak CD4+
esponse with narrow speciﬁcity [21–23]. Moreover, high IL2 levels
ave been detected in the serum of patients who cleared the virus
24]. Indeed, the presence of activated CD4+ T-cells producing IL2
nd able to prime CD8+ cytotoxic T lymphocytes (CTL) is critical
o achieve elimination of the virus [25]. Clearance of the infection
s also associated with a Th17 response and elevated plasma IL-21
evels [26].
When the initial adaptive immune response is not sufﬁcient to
lear the infection, HCV persists in the host through impairment
f the immune system. Numerous immune escape mechanisms
ave been described and extensively reviewed elsewhere [27].
hese mechanisms include protein mutations, the induction of
mmunosuppressive cytokine production (TGF beta, IL10), induc-
ion of the T-cell exhaustion phenotype (expression of negative
o-stimulatory molecules CTLA-4, PD1 and TIM-3) and an increase
n Treg frequency.
The ﬁrst study of the role of Treg during chronic HCV infection
as published a little over 10 years ago [28]. In this publication,
igher levels of circulating CD4+ CD25+ T-cells were reported in
hronic HCV patients. Furthermore, the CD4+ CD25+ T-cell fraction
hus isolated suppressed the secretion of interferon (IFN) gamma
rom HCV-speciﬁc CD8+ T-cells during a co-culture experiment.
ince this publication, numerous studies have conﬁrmed the major Disease 47 (2015) 913–917
suppressive role of Treg in the cell-mediated adaptive immune
response throughout the natural history of HCV.
3. HCV infection and Treg
As previously mentioned, acute HCV infection is often asymp-
tomatic and most patients are diagnosed during the chronic phase
of the infection. It is therefore challenging to recruit patients for
clinical studies focused on the onset of the infection. Consequently,
only a few studies have been published regarding Treg levels dur-
ing the early stages of infection. Perrella et al. were the ﬁrst to
report that Treg (CD4+ CD25+) were indeed elevated during the
acute phase of HCV infection in the peripheral blood of patients [29].
Moreover, patients who subsequently developed chronic infection
had higher blood levels of CD4+ CD25+ T-cells at the onset of the
infection than those who cleared the infection. However, this was
not the case in two subsequently published independent studies
with respect to both the CD4+ CD25+ T-cell population and the
HCV-speciﬁc CD4+ FoxP3+ population [30,31].
In the context of chronic infection, the rise in Treg levels appears
to be universal and has been described by numerous studies. Both
the CD4+ CD25+ T-cell subset and the CD4+ CD25+ FoxP3+ T-cell
subset have been found at higher levels in the peripheral blood
of chronic HCV patients when compared to healthy donors and
recovered patients [18,28,32–34]. A large number of inﬁltrating
CD4+ FoxP3+ T-cells were also reported in the livers of chronic HCV
patients, while they were almost absent from healthy livers [35].
These Treg were characterized by a fully differentiated and highly
activated phenotype, although approximately half of them did not
express CD25. Several studies have reported a correlation between
viral load and Treg levels during chronic infection, even though this
is not always the case [32,35–37].
The elevated Treg levels observed in HCV-infected patients may
result from two principal mechanisms directly inﬂuenced by the
virus. Firstly, HCV may  promote the active recruitment of exist-
ing Treg by modulating other immune cells such as dendritic cells
and B cells. In a co-culture experiment, monocyte-derived dendritic
cells (mo-DC) increased their production of the Treg-attracting
chemokines CCL17 and CCL22 when they interacted with HCV-
infected Huh7 cells [38]. A larger quantity of intrahepatic CCL22 and
CCL17 mRNA has been reported in the liver of chronic HCV patients,
thus supporting this hypothesis. Moreover, mo-DC  generated from
chronic HCV patients have been seen to possess a greater capacity to
generate Treg from naive CD4+ T-cells than mo-DC from a healthy
donor [39]. Finally, B cells exposed to HCV have been shown to
display an enhanced ability to generate Treg [40].
Secondly, HCV-infected cells may directly interact with
T-lymphocytes and favour their conversion into Treg. When acti-
vated CD4+ T cells were co-cultivated with HCV-infected Huh7
cells, they expressed higher levels of the Treg markers CD25 and
FoxP3 [41,42]. This effect was induced synergistically by TGF beta
and galectin-9, the expression of which is increased in infected
Huh7 cells. Blockade of the interaction between galectin-9 and Tim-
3 suppressed this conversion. Indeed, high levels of galectin-9 are
detected in the serum and liver of HCV-infected patients. Kupffer
cells and infected hepatocytes are the principal sources of galectin-
9 in the liver [43,44].
Alternatively, HCV proteins may  interact directly with T-cells
and render them immunosuppressive. Jurkat T-cells expressing
HCV core protein up-regulate FoxP3 and acquire suppressive func-
tion, and the transduction of HCV core protein in CD4+ T-cells
induces the expression of FoxP3 and Treg markers [45,46]. In vivo,
the immunization of mice using an adenoviral vector containing
HCV core protein enhances CD4+ and CD8+ Treg expressing CD25
and FoxP3 [47]. Furthermore, numerous reports have indicated that
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reg from HCV-infected patients have greater suppressive ability
han Treg isolated from healthy donors [18,31,34,48]. However, the
bility of HCV to infect Treg and eventually increase their suppres-
ive properties still needs to be formally demonstrated.
. Role of Treg in HCV-related ﬁbrosis
Although Treg may  favour persistence of the
irus by regulating the host anti-HCV immune response, they
ay  initially limit the extent of immune-induced liver injury. Two
ndependent studies reported that Treg from patients displaying
ctive hepatitis and elevated alanine transaminase (ALT) levels
ere less suppressive than Treg isolated from patients with
ersistently normal ALT, thus supporting this hypothesis [49,50].
However, HCV-induced ﬁbrosis is inevitable after long-term
hronic HCV infection, despite moderate inﬂammatory activity.
he role of Treg in this process is controversial. On the one
and, intrahepatic CD4+ FoxP3+ T cells are present at higher
evels in HCV-infected livers with limited ﬁbrosis, and the ratio
f FoxP3+/CD8+ cells is reduced in livers affected by severe
CV-related ﬁbrosis [35,51]. Furthermore, TGF beta produced by
CV-speciﬁc CD4+ and CD8+ T-cells appears to suppress liver ﬁbro-
enesis instead of acting as a pro-ﬁbrotic factor [52].
On the other hand, the expression of Treg markers (FoxP3,
TLA4, GITR) and Tr1 markers (CD49b, CD18, IL10) was increased in
he livers of patients with HCV-related cirrhosis when compared to
hronically infected patients without liver injury [53]. No increase
n Th1 and Th2 markers was observed. Moreover, activated CD4+
oxP3+ T cells expressing IL8 were enriched in the liver in close
roximity to alpha-SMA+ hepatic stellate cells and areas of ﬁbrosis
54]. The production of IL8 by Treg is speciﬁcally associated with
CV infection and the culture supernatant of IL8+ Treg clones acti-
ates hepatic stellate cells via IL8. Overall, these results suggest
hat different subsets of regulatory T-cells might have an opposite
nﬂuence on HCV-related ﬁbrosis.
Liver ﬁbrosis can evolve into liver cirrhosis and hepatocellular
arcinoma, both of which require liver transplantation (LT). How-
ver, if the patient is infected by HCV, graft re-infection is universal
fter LT. Moreover, graft damage and ﬁbrosis are often accelerated
fter the re-infection, leading to cirrhosis in 30% of patients within
 years and an overall reduction in patient survival compared to
ther indications. The mechanisms of accelerated HCV-induced
iver damage after LT are poorly understood. However, in recent
ears, the inﬂuence of Treg on the severity of post-transplantation
CV recurrence has been evaluated.
. Treg and HCV recurrence after liver transplantation
High levels of the intrahepatic Treg markers FoxP3, CTLA4 and
ITR have been detected in biopsies from patients experiencing
CV recurrence 1 year and 5 years after LT. In addition, the Tr1
arkers CD49b and CD18, as well as expression of the immuno-
uppressive cytokines IL10 and TGF beta were also increased and
heir levels of expression correlated positively with the severity of
he recurrence. These results suggested for the ﬁrst time that Tr1
ells play a speciﬁc deleterious role in the context of HCV recurrence
ost-transplantation [55]. It has been also observed that the expres-
ion of CD49b might be predictive of the response to combined
nterferon and ribavirin antiviral therapy after transplantation, a
igh level of CD49b RNA extracted from patient sera being associ-
ted with a lack of response to the treatment [56].Peripheral CD4+ CD25+ T-cells were also found to be elevated
oon after a post-transplant HCV recurrence and they had a greater
uppressive capacity than CD4+ CD25+ T-cells from healthy donors
48]. Interestingly, the levels and suppressive potential of CD4+ Disease 47 (2015) 913–917 915
CD25+ T-cells from patients with acute hepatitis C were similar,
suggesting that HCV reinfection reproduces the same pattern as
the primary infection in terms of Treg induction.
When Treg were analyzed during a recurrence of HCV ﬁbrosis
at least 1 year post-transplantation, severe ﬁbrosis was associated
with high levels of peripheral CD4+ CD25+ FoxP3+ Treg, high levels
of IL10-secreting CD4+ T-cells and high levels of Th17 [57]. Treg
inhibited the production of IFN gamma  from HCV-speciﬁc CD4+
T-cells but not the production of IL17, suggesting that Treg may
suppress the immune response against HCV while allowing the
establishment of a pro-inﬂammatory environment.
6. Open issues and future perspectives
Treg levels are universally elevated during chronic HCV infec-
tion and in the context of post-transplantation HCV recurrence, in
both the peripheral blood and livers of infected patients (Fig. 1).
They appear to constitute an essential immunosuppressive mech-
anism that is directly mediated by the virus, allowing its persistence
by limiting liver damage and repressing a CD8+ mediated immune
response.
Beyond this widely accepted consensus, the lack of Treg-speciﬁc
markers and common immunophenotyping protocols among
research teams render comparisons between studies hazardous
concerning more subtle aspects of the infection. In particular,
older studies tended to focus on the CD4+ CD25+ subsets while
more recent studies have often added FoxP3 as a speciﬁc marker.
These discrepancies in characterization may  explain the contradic-
tory results obtained, such as the differences between Treg levels
observed at the onset of infection. As for the use of speciﬁc markers,
it is worth mentioning that future studies could beneﬁt from the
addition of “natural” versus “induced” Foxp3+ Treg markers such
as Helios or Neuropilin-1 in order to reﬁne our knowledge of the
origin of Treg in the context of HCV infection.
Future studies could also beneﬁt from an epigenetic analysis of
the Treg-speciﬁc demethylation region (TSDR) in the FoxP3 locus
in order to accurately discriminate Treg from activated T-cells that
transiently express FoxP3. Indeed, TSDR demethylation is asso-
ciated with Treg but not activated T-cells [58]. This method has
mainly been applied to peripheral blood T-cells, although very
rarely in the context of liver transplantation, but can also be used
on parafﬁn embedded tissues [59].
Few studies have described the status of Treg during post-
transplantation HCV recurrence, although in this situation the rise
in Treg levels appears to be universal. Moreover, Treg may  actively
participate in the acceleration of ﬁbrosis in this particular context
[57]. This is an important issue because Treg have a positive effect
on graft tolerance, and strategies consisting of raising their levels in
order to reduce or even discontinue immunosuppressive therapy
are currently being investigated.
Indeed, it is now well known that calcineurin inhibitors have
a deleterious effect on Treg, while mTOR inhibitors favour their
maintenance. As antiviral therapies may also affect Treg (such as
ribavirin which reduces their suppressive capacities), ﬁnding the
right balance of medication that will favour graft acceptance and
limit the recurrence of infection might prove problematic without
further studies [60,61]. To our knowledge, the inﬂuence on Treg on
the recently approved antiviral drug sofosbuvir has not yet been
studied.
Interestingly, HCV infection does not negatively inﬂuence the
establishment of operational tolerance of the liver allograft after the
withdrawal of immunosuppression, whereas concomitant infec-
tions are generally considered to be detrimental to the process of
allograft tolerance [62]. As expected, the induction of Treg might be
involved in this phenomenon, alongside high levels of intrahepatic
916 C. Barjon et al. / Digestive and Liver Disease 47 (2015) 913–917
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[ig. 1. Known and hypothetical (italics) roles of regulatory T cells during acute, chro
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nterferon-stimulated gene expression which may  paradoxically
romote a tolerogenic micro-environment in the context of HCV
nfection.
Most of the studies referred to in this review focused on CD4+
D25+ FoxP3+ T-cells, while numerous other regulatory popula-
ions have been described. However, the lack of speciﬁc markers
inders further research on such populations. Tr1 cells have been
escribed as IL10 secreting CD4+ T-cells that promote viral per-
istence but protect against ﬁbrosis [63]. Furthermore, elevated
ost-transplantation CD49b expression suggests that Tr1 may  also
romote HCV recurrence. Moreover, the presence of regulatory
CV-speciﬁc CD8+ T-cells producing IL10 and TGF-beta has been
eported during HCV chronic infection, although intrahepatic CD8+
oxP3+ T-cells appear to be very scarce [51,64,65].
Future studies to focus on such alternative regulatory popu-
ations may  shed new light on the immunoregulatory networks
nvolved during HCV chronic infection and the recurrence of post-
ransplantation infection.
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